NTRBW and NTRB Related Headlines
Go Back- Nutriband warrants to expire Sept. 30 at $6.43 strike price
- Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
- Nutriband CEO to attend Nasdaq LaB Biotech Summit in New York
- Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
- Nutriband gets USPTO publication notice for fentanyl patch trademarks
- Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
- Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
- Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
- Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
- Nutriband selects brand name for abuse deterrent fentanyl patch
- Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
- Nutriband receives Costa Rica approval for kinesiology tapes
- Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica
- Nutriband adds two directors and provides development update
- Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
- Nutriband CEO issues year-end letter highlighting 2025 achievements
- Nutriband CEO Publishes Letter to Shareholders
- Nutriband sells majority stake in subsidiary for $5M to EarthVision Bio
- Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
- Nutriband signs letter of intent with Qvanta Group for tech collaboration
- Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration
- Nutriband responds to fentanyl weapon of mass destruction designation
- Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
- Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference
- REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
- Nutriband receives FDA feedback on abuse deterrent fentanyl patch
- Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
- Nutriband co-founder Gareth Sheridan returns as CEO
- Nutriband Co-Founder Gareth Sheridan Returns as CEO
- Nutriband partners with Brand Institute for fentanyl patch naming
- Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
- Nutriband files provisional patent for enhanced abuse deterrent technology
- Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
- Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference
- Nutriband Inc. to Present at the MicroCap Rodeo Conference
NTRBW and NTRB Related Press Releases
Go Back- Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
- Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
- Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
- Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
- Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
- Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
- Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
- Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica
- Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
- Nutriband CEO Publishes Letter to Shareholders
- Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
- Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration
- Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
- Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference
- REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
- Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
- Nutriband Co-Founder Gareth Sheridan Returns as CEO
- Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
- Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
- Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference
- Nutriband Inc. to Present at the MicroCap Rodeo Conference
